

01-14-04

PATENT
674575-2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : FAGAN, Richard Joseph et al.
Title : INTERFERON GAMMA-LIKE PROTEINS
Appl. No. : 10/600,790
Filing Date : June 20, 2003
Examiner : To be assigned
Art Unit : 1644

EXPRESS MAIL

Mailing Label Number: EV 287820789 US

Date of Deposit: January 13, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: **Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Charles J. Sullivan
(Typed or printed name of person mailing paper or fee)

Charles J. Sullivan
(Signature of person mailing paper or fee)

**AMENDMENT AND RESPONSE TO
NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

This is in response to the Notice to File Missing Parts of Nonprovisional Application mailed November 13, 2003, setting a two-month term for reply. As this response is being filed before the end of the period for reply, it is believed that no fees are required for entry of this paper. However, the Commissioner is hereby authorized to charge any required fee, or credit any overpayment in fees, to Deposit Account 50-0320.



PATENT
674575-2003

Applicants respectfully request acceptance of the enclosed executed declaration, a check in the amount of \$130.00 to cover the required surcharge for late filing of the declaration, the paper copy and computer readable form of the Sequence Listing, and thirty-three (33) sheets of formal drawings (Figs. 1-18F).



AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

IN THE SPECIFICATION:

Kindly amend the specification, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows: Page 50, line 6 to page 51, line 8, please rewrite the paragraph thereat as follows:

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Results from Inpharmatica Genome Threader query using SEQ ID NO:2.

Figure 2: Alignment generated by Inpharmatica Genome Threader between SEQ ID NO:2 and closest related structure (SEQ ID NO: 21).

Figure 3: INSP037 predicted nucleotide sequence (comprising SEQ ID NO:16) with translation (SEQ ID NO:2).

Figure 4: INSP037 cloned nucleotide sequence (comprising SEQ ID NO:17) with translation (SEQ ID NO:2), demonstrating that the predicted and cloned sequence for INSP037 are identical.

Figure 5: Map of PCRII-TOPO-IPAAA44548.

Figure 6: Map of expression vector pEAK12d.

Figure 7: Map of plasmid pDONR201.

Figure 8: Map of expression vector pEAK12d-IPAAA44548-6HIS.

Figure 9: Map of *E. coli* expression vector pDEST14.

Figure 10: Map of plasmid pDEST14-IPAAA44548-6HIS.

Figure 11: Nucleotide sequence of PCRII-TOPO-IPAAA44548 (SEQ ID NO: 18).

Figure 12: Nucleotide sequence of pDEST14-IPAAA44548-6HIS (SEQ ID NO: 19).

Figure 13: Nucleotide sequence of pEAK12D-IPAAA44548-6HIS (SEQ ID NO: 20).